Anixa Biosciences, Inc. (ANIX)
USD 2.55
(-1.92%)
USD 2.55
(-1.92%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -740 Thousand USD | 93.9% |
| 2022 | -12.13 Million USD | 57.95% |
| 2021 | -28.86 Million USD | -353.78% |
| 2020 | -6.36 Million USD | -82.2% |
| 2019 | -3.49 Million USD | -14.26% |
| 2018 | -3.05 Million USD | 8.49% |
| 2017 | -3.33 Million USD | -298.35% |
| 2016 | 1.68 Million USD | 138.53% |
| 2015 | -4.36 Million USD | -29.99% |
| 2014 | -3.36 Million USD | -172.28% |
| 2013 | 4.65 Million USD | 1612.73% |
| 2012 | -307.42 Thousand USD | -107.27% |
| 2011 | 4.22 Million USD | 8.19% |
| 2010 | 3.9 Million USD | 10.06% |
| 2009 | 3.54 Million USD | -21.51% |
| 2008 | 4.52 Million USD | 775.7% |
| 2007 | -669.14 Thousand USD | 47.79% |
| 2006 | -1.28 Million USD | -153.03% |
| 2005 | -506.51 Thousand USD | 49.49% |
| 2004 | -1 Million USD | 2.03% |
| 2003 | -1.02 Million USD | -19.74% |
| 2002 | -854.82 Thousand USD | 35.09% |
| 2001 | -1.31 Million USD | -16.12% |
| 2000 | -1.13 Million USD | 29.12% |
| 1999 | -1.6 Million USD | 70.37% |
| 1998 | -5.4 Million USD | 56.1% |
| 1997 | -12.3 Million USD | 44.59% |
| 1996 | -22.2 Million USD | -149.44% |
| 1995 | -8.9 Million USD | -43.55% |
| 1994 | -6.2 Million USD | 25.3% |
| 1993 | -8.3 Million USD | -102.44% |
| 1992 | -4.1 Million USD | 0.0% |
| 1991 | -4.1 Million USD | -95.24% |
| 1990 | -2.1 Million USD | 4.55% |
| 1989 | -2.2 Million USD | -29.41% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -988 Thousand USD | -16.78% |
| 2024 Q1 | -836 Thousand USD | -12.97% |
| 2024 Q2 | -846 Thousand USD | -1.2% |
| 2023 Q1 | -9.58 Million USD | 21.07% |
| 2023 Q3 | -3.01 Million USD | 44.47% |
| 2023 Q2 | -5.42 Million USD | 43.41% |
| 2023 Q4 | -740 Thousand USD | 75.42% |
| 2023 FY | -740 Thousand USD | 93.9% |
| 2022 Q1 | -29.53 Million USD | -2.29% |
| 2022 FY | -12.13 Million USD | 57.95% |
| 2022 Q3 | -24.02 Million USD | 12.62% |
| 2022 Q2 | -27.49 Million USD | 6.91% |
| 2022 Q4 | -12.13 Million USD | 49.47% |
| 2021 FY | -28.86 Million USD | -353.78% |
| 2021 Q1 | -11.94 Million USD | -87.71% |
| 2021 Q2 | -27.67 Million USD | -131.77% |
| 2021 Q4 | -28.86 Million USD | -6.09% |
| 2021 Q3 | -27.21 Million USD | 1.68% |
| 2020 Q4 | -6.36 Million USD | -8.58% |
| 2020 Q3 | -5.85 Million USD | -108.78% |
| 2020 Q1 | -2.72 Million USD | 21.88% |
| 2020 Q2 | -2.8 Million USD | -2.89% |
| 2020 FY | -6.36 Million USD | -82.2% |
| 2019 Q4 | -3.49 Million USD | 20.59% |
| 2019 Q1 | -4.15 Million USD | -35.89% |
| 2019 Q2 | -3.82 Million USD | 7.95% |
| 2019 FY | -3.49 Million USD | -14.26% |
| 2019 Q3 | -4.39 Million USD | -15.03% |
| 2018 FY | -3.05 Million USD | 8.49% |
| 2018 Q2 | -4.17 Million USD | -46.56% |
| 2018 Q3 | -2.59 Million USD | 37.9% |
| 2018 Q1 | -2.84 Million USD | 14.75% |
| 2018 Q4 | -3.05 Million USD | -17.94% |
| 2017 Q1 | 1.6 Million USD | 164.3% |
| 2017 FY | -3.33 Million USD | -298.35% |
| 2017 Q3 | 166.23 Thousand USD | 35.03% |
| 2017 Q2 | 123.1 Thousand USD | -92.31% |
| 2017 Q4 | -3.33 Million USD | -2108.86% |
| 2016 FY | 1.68 Million USD | 138.53% |
| 2016 Q2 | -2.61 Million USD | 34.38% |
| 2016 Q3 | -2.04 Million USD | 21.55% |
| 2016 Q1 | -3.98 Million USD | 8.89% |
| 2016 Q4 | -2.48 Million USD | -21.43% |
| 2015 FY | -4.36 Million USD | -29.99% |
| 2015 Q1 | -7.8 Million USD | -132.34% |
| 2015 Q3 | -5.16 Million USD | 15.12% |
| 2015 Q4 | -4.36 Million USD | 15.34% |
| 2015 Q2 | -6.08 Million USD | 22.14% |
| 2014 FY | -3.36 Million USD | -172.28% |
| 2014 Q1 | 6.4 Million USD | 37.7% |
| 2014 Q2 | 6 Million USD | -6.15% |
| 2014 Q4 | -3.36 Million USD | -208.27% |
| 2014 Q3 | 3.1 Million USD | -48.34% |
| 2013 Q1 | 3.69 Million USD | 1301.72% |
| 2013 FY | 4.65 Million USD | 1612.73% |
| 2013 Q4 | 4.65 Million USD | 4.07% |
| 2013 Q3 | 4.46 Million USD | 6.91% |
| 2013 Q2 | 4.17 Million USD | 13.14% |
| 2012 Q2 | 4.86 Million USD | 7.32% |
| 2012 Q3 | 4.89 Million USD | 0.6% |
| 2012 Q4 | -307.42 Thousand USD | -106.28% |
| 2012 Q1 | 4.53 Million USD | 7.36% |
| 2012 FY | -307.42 Thousand USD | -107.27% |
| 2011 Q2 | 4.65 Million USD | 15.71% |
| 2011 Q3 | 4.44 Million USD | -4.39% |
| 2011 Q4 | 4.22 Million USD | -5.0% |
| 2011 Q1 | 4.02 Million USD | 2.95% |
| 2011 FY | 4.22 Million USD | 8.19% |
| 2010 Q1 | 3.8 Million USD | 7.17% |
| 2010 FY | 3.9 Million USD | 10.06% |
| 2010 Q4 | 3.9 Million USD | 8.77% |
| 2010 Q3 | 3.59 Million USD | -8.51% |
| 2010 Q2 | 3.92 Million USD | 3.2% |
| 2009 FY | 3.54 Million USD | -21.51% |
| 2009 Q4 | 3.54 Million USD | -24.16% |
| 2009 Q1 | 3.28 Million USD | -27.37% |
| 2009 Q2 | 3.7 Million USD | 12.94% |
| 2009 Q3 | 4.67 Million USD | 26.16% |
| 2008 Q4 | 4.52 Million USD | -0.46% |
| 2008 FY | 4.52 Million USD | 775.7% |
| 2008 Q1 | 4.2 Million USD | 728.62% |
| 2008 Q2 | 4.23 Million USD | 0.71% |
| 2008 Q3 | 4.54 Million USD | 7.23% |
| 2007 Q3 | -652.76 Thousand USD | 14.78% |
| 2007 Q2 | -765.99 Thousand USD | 7.49% |
| 2007 Q1 | -828.01 Thousand USD | 35.4% |
| 2007 Q4 | -669.14 Thousand USD | -2.51% |
| 2007 FY | -669.14 Thousand USD | 47.79% |
| 2006 Q2 | -732.02 Thousand USD | 9.52% |
| 2006 FY | -1.28 Million USD | -153.03% |
| 2006 Q1 | -809.06 Thousand USD | -59.73% |
| 2006 Q4 | -1.28 Million USD | -109.67% |
| 2006 Q3 | -611.26 Thousand USD | 16.5% |
| 2005 Q3 | -581.79 Thousand USD | 9.18% |
| 2005 Q4 | -506.51 Thousand USD | 12.94% |
| 2005 FY | -506.51 Thousand USD | 49.49% |
| 2005 Q1 | -1.01 Million USD | -0.92% |
| 2005 Q2 | -640.62 Thousand USD | 36.69% |
| 2004 FY | -1 Million USD | 2.03% |
| 2004 Q4 | -1 Million USD | 3.61% |
| 2004 Q1 | -868.17 Thousand USD | 15.18% |
| 2004 Q2 | -1.24 Million USD | -43.21% |
| 2004 Q3 | -1.04 Million USD | 16.33% |
| 2003 Q2 | -407.79 Thousand USD | 32.37% |
| 2003 Q1 | -602.94 Thousand USD | 29.47% |
| 2003 Q4 | -1.02 Million USD | 3.13% |
| 2003 Q3 | -1.05 Million USD | -159.11% |
| 2003 FY | -1.02 Million USD | -19.74% |
| 2002 FY | -854.82 Thousand USD | 35.09% |
| 2002 Q3 | -1.3 Million USD | 39.23% |
| 2002 Q1 | -3.45 Million USD | -162.36% |
| 2002 Q2 | -2.14 Million USD | 38.0% |
| 2002 Q4 | -854.82 Thousand USD | 34.33% |
| 2001 FY | -1.31 Million USD | -16.12% |
| 2001 Q3 | -2.01 Million USD | -1176.73% |
| 2001 Q2 | -157.86 Thousand USD | 77.55% |
| 2001 Q4 | -1.31 Million USD | 34.66% |
| 2001 Q1 | -703.12 Thousand USD | 38.0% |
| 2000 Q3 | -2.62 Million USD | 26.98% |
| 2000 FY | -1.13 Million USD | 29.12% |
| 2000 Q4 | -1.13 Million USD | 56.73% |
| 2000 Q2 | -3.58 Million USD | -70.9% |
| 2000 Q1 | -2.1 Million USD | -31.25% |
| 1999 Q3 | -2.3 Million USD | 37.84% |
| 1999 Q4 | -1.6 Million USD | 30.43% |
| 1999 Q2 | -3.7 Million USD | 15.91% |
| 1999 Q1 | -4.4 Million USD | 18.52% |
| 1999 FY | -1.6 Million USD | 70.37% |
| 1998 Q3 | -6.1 Million USD | 23.75% |
| 1998 FY | -5.4 Million USD | 56.1% |
| 1998 Q4 | -5.4 Million USD | 11.48% |
| 1998 Q1 | -11.2 Million USD | 8.94% |
| 1998 Q2 | -8 Million USD | 28.57% |
| 1997 Q3 | -15.8 Million USD | 14.59% |
| 1997 Q4 | -12.3 Million USD | 22.15% |
| 1997 Q2 | -18.5 Million USD | 5.13% |
| 1997 FY | -12.3 Million USD | 44.59% |
| 1997 Q1 | -19.5 Million USD | 12.16% |
| 1996 Q4 | -22.2 Million USD | -3.74% |
| 1996 Q1 | -10.2 Million USD | -14.61% |
| 1996 Q2 | -13.9 Million USD | -36.27% |
| 1996 Q3 | -21.4 Million USD | -53.96% |
| 1996 FY | -22.2 Million USD | -149.44% |
| 1995 FY | -8.9 Million USD | -43.55% |
| 1995 Q1 | -5.7 Million USD | 8.06% |
| 1995 Q2 | -6.9 Million USD | -21.05% |
| 1995 Q4 | -8.9 Million USD | -2.3% |
| 1995 Q3 | -8.7 Million USD | -26.09% |
| 1994 Q2 | -6.8 Million USD | 8.11% |
| 1994 Q1 | -7.4 Million USD | 10.84% |
| 1994 FY | -6.2 Million USD | 25.3% |
| 1994 Q4 | -6.2 Million USD | 11.43% |
| 1994 Q3 | -7 Million USD | -2.94% |
| 1993 Q4 | -8.3 Million USD | -9.21% |
| 1993 FY | -8.3 Million USD | -102.44% |
| 1993 Q1 | -5.2 Million USD | -26.83% |
| 1993 Q2 | -5.8 Million USD | -11.54% |
| 1993 Q3 | -7.6 Million USD | -31.03% |
| 1992 FY | -4.1 Million USD | 0.0% |
| 1992 Q2 | -4.3 Million USD | 0.0% |
| 1992 Q4 | -4.1 Million USD | 0.0% |
| 1992 Q3 | -4.1 Million USD | 4.65% |
| 1992 Q1 | -4.3 Million USD | -4.88% |
| 1991 Q3 | -2.1 Million USD | 30.0% |
| 1991 FY | -4.1 Million USD | -95.24% |
| 1991 Q4 | -4.1 Million USD | -95.24% |
| 1991 Q1 | -2.1 Million USD | 0.0% |
| 1991 Q2 | -3 Million USD | -42.86% |
| 1990 FY | -2.1 Million USD | 4.55% |
| 1990 Q4 | -2.1 Million USD | 4.55% |
| 1990 Q3 | -2.2 Million USD | -29.41% |
| 1990 Q1 | -2.5 Million USD | -13.64% |
| 1990 Q2 | -1.7 Million USD | 32.0% |
| 1989 FY | -2.2 Million USD | -29.41% |
| 1989 Q4 | -2.2 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 98.677% |
| Alkermes plc | -166.73 Million USD | 99.556% |
| Agenus Inc. | 274.13 Million USD | 100.27% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 100.04% |
| Aptorum Group Limited | 1.35 Million USD | 154.53% |
| Ardelyx, Inc. | 34.51 Million USD | 102.144% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 117.29% |
| Bicycle Therapeutics plc | -481.46 Million USD | 99.846% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 102.046% |
| ChromaDex Corporation | -24.04 Million USD | 96.923% |
| Chimerix, Inc. | -25.51 Million USD | 97.1% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 110.62% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 96.875% |
| CRISPR Therapeutics AG | -150.84 Million USD | 99.509% |
| Precision BioSciences, Inc. | -85.41 Million USD | 99.134% |
| Dyadic International, Inc. | -6.37 Million USD | 88.398% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 95.356% |
| Fortress Biotech, Inc. | 7.66 Million USD | 109.654% |
| Lantern Pharma Inc. | -21.7 Million USD | 96.59% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 99.331% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 91.338% |
| Incyte Corporation | -3.17 Billion USD | 99.977% |
| IO Biotech, Inc. | -140.69 Million USD | 99.474% |
| Jaguar Health, Inc. | 29.39 Million USD | 102.518% |
| Novavax, Inc. | -298.29 Million USD | 99.752% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 113.865% |
| Opthea Limited | 28.15 Million USD | 102.628% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 95.592% |
| ContextLogic Inc. | -232 Million USD | 99.681% |
| MiMedx Group, Inc. | -33.9 Million USD | 97.817% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 107.258% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 68.063% |
| NextCure, Inc. | -6.47 Million USD | 88.575% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 98.535% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 88.399% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 106.084% |
| Vaxcyte, Inc. | -368.22 Million USD | 99.799% |
| PDS Biotechnology Corporation | -32.7 Million USD | 97.738% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 104.283% |
| Pharming Group N.V. | 109.8 Million USD | 100.674% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 95.746% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 99.578% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 96.004% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 96.004% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 89.577% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 87.372% |
| Acelyrin, Inc. | -216.9 Million USD | 99.659% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 86.81% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 57.077% |
| Summit Therapeutics Inc. | 34.67 Million USD | 102.134% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 89.122% |
| Senti Biosciences, Inc. | 1.74 Million USD | 142.529% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 99.599% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 99.045% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 87.793% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 841.713% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 217.834% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 99.368% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 99.56% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 100.667% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 90.258% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 99.427% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 110.733% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 99.695% |
| Immix Biopharma, Inc. | -17.5 Million USD | 95.774% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 99.766% |
| MEI Pharma, Inc. | -3.7 Million USD | 80.027% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 105.915% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 100.458% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 102.663% |
| Fortress Biotech, Inc. | 7.66 Million USD | 109.654% |
| Precigen, Inc. | -481 Thousand USD | -53.846% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 105.255% |
| AlloVir, Inc. | -62.69 Million USD | 98.82% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 98.669% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 101.2% |
| ImmuCell Corporation | 10.99 Million USD | 106.733% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 99.52% |
| Onconetix, Inc. | 5.33 Million USD | 113.88% |
| PureTech Health plc | -167.19 Million USD | 99.557% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 97.571% |
| Elevation Oncology, Inc. | -19.11 Million USD | 96.129% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 84.926% |
| Seer, Inc. | -4.24 Million USD | 82.547% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 96.921% |
| Innoviva, Inc. | 255.56 Million USD | 100.29% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 98.675% |
| ESSA Pharma Inc. | -33.62 Million USD | 97.799% |
| GlycoMimetics, Inc. | -40.98 Million USD | 98.194% |
| GT Biopharma, Inc. | -1.02 Million USD | 27.522% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 98.908% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 101.208% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 99.448% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 94.659% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 97.437% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -882.292% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 97.602% |
| Aptose Biosciences Inc. | -8.19 Million USD | 90.97% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 76.35% |
| Soligenix, Inc. | -4.95 Million USD | 85.055% |
| Century Therapeutics, Inc. | 847 Thousand USD | 187.367% |
| Kura Oncology, Inc. | -20.11 Million USD | 96.322% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 98.192% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 91.188% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 140.622% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 76.853% |
| Autolus Therapeutics plc | -186.59 Million USD | 99.603% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 98.499% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 99.732% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 102.159% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 100.45% |
| GRI Bio, Inc. | -1.79 Million USD | 58.751% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 91.762% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 97.775% |
| IGM Biosciences, Inc. | -72.6 Million USD | 98.981% |
| INmune Bio, Inc. | -25.41 Million USD | 97.088% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 100.49% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 98.539% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 95.446% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 74.349% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 101.947% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 98.203% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 102.321% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 100.196% |
| Verastem, Inc. | -37.27 Million USD | 98.015% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 91.844% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 98.573% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 95.111% |
| Histogen Inc. | -7.48 Million USD | 90.116% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 96.575% |
| Surrozen, Inc. | -32.66 Million USD | 97.735% |
| Organovo Holdings, Inc. | -1.5 Million USD | 50.896% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 82.396% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 103.903% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 128.287% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 117.806% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 91.171% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 98.297% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 94.923% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 99.766% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -2.485% |
| Apollomics, Inc. | -27.39 Million USD | 97.299% |
| Amarin Corporation plc | -191.04 Million USD | 99.613% |
| Mesoblast Limited | 55.96 Million USD | 101.322% |
| Turnstone Biologics Corp. | -14.58 Million USD | 94.926% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 97.074% |
| Synaptogenix, Inc. | -28.66 Million USD | 97.418% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 20.94% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 101.519% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 14.162% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 89.816% |
| Exelixis, Inc. | -73.05 Million USD | 98.987% |
| Better Therapeutics, Inc. | -860 Thousand USD | 13.953% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 96.918% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 99.693% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 200.534% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 90.051% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 159.011% |
| Gritstone bio, Inc. | 39.49 Million USD | 101.874% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 99.12% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 71.886% |
| Avid Bioservices, Inc. | 169.72 Million USD | 100.436% |
| Insmed Incorporated | 721.62 Million USD | 100.103% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 91.905% |
| MediWound Ltd. | -5.32 Million USD | 86.095% |
| OmniAb, Inc. | 9.2 Million USD | 108.041% |
| Alector, Inc. | -35.63 Million USD | 97.924% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 100.861% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 84.984% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 105.59% |
| Zai Lab Limited | -775 Million USD | 99.905% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 100.217% |
| Aura Biosciences, Inc. | -21.52 Million USD | 96.562% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 99.103% |
| Immunic, Inc. | -45.34 Million USD | 98.368% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 99.617% |
| Veracyte, Inc. | -203.82 Million USD | 99.637% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 100.116% |
| FibroGen, Inc. | 56.76 Million USD | 101.304% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 108.31% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 73.825% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 64.257% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 100.016% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 77.851% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 99.554% |
| TG Therapeutics, Inc. | 17.86 Million USD | 104.143% |
| Galecto, Inc. | -21.21 Million USD | 96.512% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 96.889% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 100.047% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 96.976% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 93.569% |
| XBiotech Inc. | -200.02 Million USD | 99.63% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 99.12% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 116.343% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 97.901% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 99.042% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 113.003% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 99.566% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 99.199% |
| Vaxxinity, Inc. | 10.13 Million USD | 107.304% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 100.101% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 93.127% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 98.878% |
| NexImmune, Inc. | -3.13 Million USD | 76.385% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 78.567% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 95.103% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 97.269% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 91.756% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -494.02% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 98.176% |
| Ainos, Inc. | 4.07 Million USD | 118.146% |
| Pluri Inc. | 22.82 Million USD | 103.241% |
| Prothena Corporation plc | -608.34 Million USD | 99.878% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 99.377% |
| Celularity Inc. | 65.19 Million USD | 101.135% |
| Rallybio Corporation | -24.1 Million USD | 96.93% |
| Cue Biopharma, Inc. | -33.81 Million USD | 97.812% |
| MeiraGTx Holdings plc | -40.3 Million USD | 98.164% |
| Omeros Corporation | 331.17 Million USD | 100.223% |
| Humacyte, Inc. | -22.48 Million USD | 96.709% |
| Immunocore Holdings plc | -358.59 Million USD | 99.794% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 96.989% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 97.605% |
| Blueprint Medicines Corporation | 702.83 Million USD | 100.105% |
| CalciMedica, Inc. | -5.53 Million USD | 86.618% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 99.607% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 92.755% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 98.152% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 97.775% |
| Pulmatrix, Inc. | -10.41 Million USD | 92.896% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 87.619% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 98.06% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 99.336% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 98.766% |
| Cytokinetics, Incorporated | 642.37 Million USD | 100.115% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 87.292% |
| Nutriband Inc. | -251.65 Thousand USD | -194.051% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 97.831% |
| Vor Biopharma Inc. | 4.3 Million USD | 117.209% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 99.988% |
| Evogene Ltd. | -19.63 Million USD | 96.231% |
| ProKidney Corp. | -56.23 Million USD | 98.684% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 98.48% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 91.989% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 100.054% |
| CorMedix Inc. | -43.05 Million USD | 98.281% |
| BioLineRx Ltd. | 7.33 Million USD | 110.087% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 97.306% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 101.604% |
| Atai Life Sciences N.V. | -28.55 Million USD | 97.409% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 133.176% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 96.757% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 104.173% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 99.014% |
| MediciNova, Inc. | -50.78 Million USD | 98.543% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 99.061% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -3189.62% |
| GeoVax Labs, Inc. | -6.45 Million USD | 88.532% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 99.63% |
| Biomea Fusion, Inc. | -166.57 Million USD | 99.556% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 99.587% |
| Mereo BioPharma Group plc | -51.46 Million USD | 98.562% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 99.22% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 99.748% |
| Absci Corporation | -72.59 Million USD | 98.981% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 116.207% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 99.684% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 99.215% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 99.227% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 98.106% |
| Allakos Inc. | -24.97 Million USD | 97.037% |
| Imunon, Inc. | -4.21 Million USD | 82.439% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 94.98% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 99.453% |
| BioAtla, Inc. | -109.01 Million USD | 99.321% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 200.534% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 21.193% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 106.184% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 96.51% |
| XOMA Corporation | -29 Million USD | 97.448% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 95.531% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 91.792% |
| aTyr Pharma, Inc. | -7.44 Million USD | 90.066% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 99.406% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 99.645% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 99.095% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 99.202% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 13.872% |
| Akari Therapeutics, Plc | -3.84 Million USD | 80.754% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 145.598% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 100.054% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 37.718% |
| UroGen Pharma Ltd. | 4.39 Million USD | 116.853% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 100.652% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 1128.321% |
| Orgenesis Inc. | 21.78 Million USD | 103.397% |
| Entera Bio Ltd. | -10.62 Million USD | 93.038% |
| GH Research PLC | -78.07 Million USD | 99.052% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 96.68% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 97.224% |
| Xencor, Inc. | 29.64 Million USD | 102.496% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 62.433% |
| Replimune Group, Inc. | 1.41 Million USD | 152.408% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -202.154% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 99.415% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 37.718% |
| Portage Biotech Inc. | -4.98 Million USD | 85.144% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -3189.62% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 98.881% |
| OncoCyte Corporation | -6.56 Million USD | 88.725% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 182.459% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 83.756% |
| Purple Biotech Ltd. | -14.13 Million USD | 94.766% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 96.885% |
| scPharmaceuticals Inc. | -6.54 Million USD | 88.694% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 95.567% |
| HilleVax, Inc. | -165.48 Million USD | 99.553% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 70.843% |
| Tharimmune, Inc. | -10.93 Million USD | 93.233% |
| Genprex, Inc. | -6.73 Million USD | 89.017% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 99.799% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 99.163% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 47.181% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 77.69% |
| OKYO Pharma Limited | -826.84 Thousand USD | 10.504% |
| Savara Inc. | 153 Thousand USD | 583.66% |
| Curis, Inc. | -23.88 Million USD | 96.902% |
| Daré Bioscience, Inc. | -5.15 Million USD | 85.653% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 4.641% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 88.08% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 162.447% |
| BeiGene, Ltd. | -2.25 Billion USD | 99.967% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 105.997% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 99.878% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 99.601% |
| Erasca, Inc. | -37.21 Million USD | 98.012% |
| bluebird bio, Inc. | 108.57 Million USD | 100.682% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 42.542% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 100.195% |
| DBV Technologies S.A. | -126.98 Million USD | 99.417% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 42.542% |
| Moderna, Inc. | -2.9 Billion USD | 99.975% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 92.852% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 93.191% |
| Molecular Templates, Inc. | 707 Thousand USD | 204.668% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 97.641% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 100.213% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 99.098% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 99.193% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 97.707% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 97.847% |
| MacroGenics, Inc. | -66.98 Million USD | 98.895% |
| RenovoRx, Inc. | -1.17 Million USD | 36.914% |
| Adicet Bio, Inc. | -138.78 Million USD | 99.467% |
| Prime Medicine, Inc. | -27.94 Million USD | 97.352% |
| Aditxt, Inc. | 18.12 Million USD | 104.084% |
| Adagene Inc. | -87.62 Million USD | 99.156% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 82.235% |
| Quantum-Si incorporated | -118.55 Million USD | 99.376% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 102.055% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 90.099% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 98.475% |
| SciSparc Ltd. | -2.06 Million USD | 64.165% |
| Vericel Corporation | 1.27 Million USD | 157.948% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 93.829% |
| Minerva Neurosciences, Inc. | 41 Million USD | 101.805% |
| Generation Bio Co. | 31.44 Million USD | 102.353% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 99.578% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 97.607% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 100.635% |
| Invivyd, Inc. | -198.47 Million USD | 99.627% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 99.18% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 69.137% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 98.955% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 89.158% |
| 2seventy bio, Inc. | 181.71 Million USD | 100.407% |
| ADMA Biologics, Inc. | 90.06 Million USD | 100.822% |
| Clene Inc. | 3.34 Million USD | 122.156% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 91.853% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 96.56% |
| GeoVax Labs, Inc. | -6.45 Million USD | 88.532% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 99.785% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 97.154% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 100.417% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 81.914% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 114.794% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 85.794% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 99.432% |
| Evaxion Biotech A/S | 5.28 Million USD | 113.997% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 99.343% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 99.436% |
| Trevena, Inc. | 2.25 Million USD | 132.772% |
| Surrozen, Inc. | -32.66 Million USD | 97.735% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 98.563% |
| Cingulate Inc. | 3.08 Million USD | 124.005% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 74.804% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 110.296% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 92.035% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 99.067% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 99.437% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 99.299% |
| Clearmind Medicine Inc. | -3.94 Million USD | 81.231% |
| Kronos Bio, Inc. | -36.05 Million USD | 97.948% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 107.865% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 150.75% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 98.636% |
| Statera Biopharma, Inc. | 14.41 Million USD | 105.133% |
| ImmunityBio, Inc. | 618.22 Million USD | 100.12% |
| Korro Bio, Inc. | -132.94 Million USD | 99.443% |
| Kineta, Inc. | -4.54 Million USD | 83.704% |
| BioVie Inc. | -17.73 Million USD | 95.827% |
| Codexis, Inc. | -43.27 Million USD | 98.29% |
| Celularity Inc. | 65.19 Million USD | 101.135% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 76.649% |
| Celcuity Inc. | 6.78 Million USD | 110.909% |
| Virax Biolabs Group Limited | -3.36 Million USD | 78.009% |
| Cibus, Inc. | -8.07 Million USD | 90.839% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 82.502% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 116.193% |
| IN8bio, Inc. | -16.38 Million USD | 95.485% |
| Kodiak Sciences Inc. | -103.87 Million USD | 99.288% |
| Annexon, Inc. | -193.75 Million USD | 99.618% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 2155.556% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 95.771% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 78.935% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 100.07% |
| Eyenovia, Inc. | 1.25 Million USD | 158.791% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 102.75% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 77.182% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 97.774% |
| Arcellx, Inc. | -296.95 Million USD | 99.751% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 96.206% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 98.743% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 96.43% |
| Moolec Science SA | 117.61 Thousand USD | 729.166% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 98.073% |
| Geron Corporation | 14.76 Million USD | 105.013% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 98.048% |
| Royalty Pharma plc | 5.65 Billion USD | 100.013% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 99.477% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 89.413% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 86.201% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 99.474% |
| Humacyte, Inc. | -22.48 Million USD | 96.709% |
| Structure Therapeutics Inc. | -124.33 Million USD | 99.405% |
| 89bio, Inc. | -289.05 Million USD | 99.744% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 97.068% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 58.497% |
| Genelux Corporation | -6.89 Million USD | 89.274% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 97.617% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 100.885% |
| Notable Labs, Ltd. | -9.77 Million USD | 92.43% |
| Liquidia Corporation | -80.17 Million USD | 99.077% |
| Mustang Bio, Inc. | -3.73 Million USD | 80.193% |
| Immunovant, Inc. | -635.22 Million USD | 99.884% |
| Quantum-Si incorporated | -118.55 Million USD | 99.376% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 95.787% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 82.139% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 109.219% |
| Acasti Pharma Inc. | -23 Million USD | 96.783% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 78.023% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 95.446% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 99.463% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 76.254% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 96.671% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 96.015% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 99.563% |
| PepGen Inc. | -60.67 Million USD | 98.78% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 96.779% |
| United Therapeutics Corporation | -507.7 Million USD | 99.854% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 96.131% |
| Solid Biosciences Inc. | -47.75 Million USD | 98.45% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 14.162% |
| Immuneering Corporation | -54.94 Million USD | 98.653% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 82.396% |
| Silo Pharma, Inc. | -3.52 Million USD | 79.003% |
| Belite Bio, Inc | -87.27 Million USD | 99.152% |
| XOMA Corporation | -29 Million USD | 97.448% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 98.953% |
| Bionomics Limited | 227 Million USD | 100.326% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 99.364% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 70.786% |
| uniQure N.V. | -102.95 Million USD | 99.281% |
| Cassava Sciences, Inc. | -121.13 Million USD | 99.389% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 82.235% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 101.807% |
| Forte Biosciences, Inc. | -11.96 Million USD | 93.813% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 76.084% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 798.113% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 77.182% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 108.31% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 90.022% |
| Altimmune, Inc. | -134.48 Million USD | 99.45% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 100.374% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 70.786% |
| Compugen Ltd. | -12.9 Million USD | 94.265% |
| Peak Bio, Inc. | 10.34 Million USD | 107.157% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -161.484% |
| Benitec Biopharma Inc. | -50.58 Million USD | 98.537% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 99.291% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 103.767% |
| Zura Bio Limited | -99.8 Million USD | 99.259% |
| PolyPid Ltd. | 6.17 Million USD | 111.994% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 100.998% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 103.767% |
| Instil Bio, Inc. | 75.35 Million USD | 100.982% |
| argenx SE | -2.02 Billion USD | 99.964% |
| Immunome, Inc. | -97.02 Million USD | 99.237% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 96.71% |
| Verona Pharma plc | -220.44 Million USD | 99.664% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 98.969% |
| Shattuck Labs, Inc. | -121.42 Million USD | 99.391% |
| CervoMed Inc. | -7.79 Million USD | 90.504% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 99.601% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 83.078% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 99.438% |
| Moolec Science SA | 117.61 Thousand USD | 729.166% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 67.657% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 104.655% |
| AnaptysBio, Inc. | -18.15 Million USD | 95.923% |
| Design Therapeutics, Inc. | -18.15 Million USD | 95.923% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 98.949% |
| NeurAxis, Inc. | 145.7 Thousand USD | 607.893% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 106.588% |
| Lumos Pharma, Inc. | -28.49 Million USD | 97.403% |
| Achilles Therapeutics plc | -126.92 Million USD | 99.417% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 98.969% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -12.851% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 96.438% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 150.75% |
| Nutriband Inc. | -251.65 Thousand USD | -194.051% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 94.382% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 90.054% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 100.218% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 103.118% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 99.835% |
| Palisade Bio, Inc. | -12.06 Million USD | 93.866% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 99.473% |
| Beam Therapeutics Inc. | -262.72 Million USD | 99.718% |
| Neurogene Inc. | -131.95 Million USD | 99.439% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 103.392% |
| AEON Biopharma, Inc. | -4.88 Million USD | 84.836% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 99.804% |
| Sesen Bio, Inc. | -112.55 Million USD | 99.343% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 99.259% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 68.481% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 98.104% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 99.111% |
| Athira Pharma, Inc. | -88.99 Million USD | 99.169% |
| Vaccinex, Inc. | -1.28 Million USD | 42.547% |
| HCW Biologics Inc. | 2.85 Million USD | 125.904% |
| XOMA Corporation | -29 Million USD | 97.448% |
| Nektar Therapeutics | 210.24 Million USD | 100.352% |
| Arvinas, Inc. | -313.8 Million USD | 99.764% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 145.598% |
| Merus N.V. | -192.88 Million USD | 99.616% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 101.234% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 89.334% |
| Rezolute, Inc. | -68.16 Million USD | 98.914% |
| Clene Inc. | 3.34 Million USD | 122.156% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 94.388% |
| BeyondSpring Inc. | -13.75 Million USD | 94.62% |
| Synlogic, Inc. | -6.68 Million USD | 88.93% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 165.256% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 91.248% |
| Peak Bio, Inc. | 10.34 Million USD | 107.157% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 99.102% |
| Krystal Biotech, Inc. | -350.23 Million USD | 99.789% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 100.596% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 99.562% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 76.561% |
| MannKind Corporation | 143.89 Million USD | 100.514% |
| Ikena Oncology, Inc. | -109.15 Million USD | 99.322% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 90.226% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 97.764% |
| Gossamer Bio, Inc. | 180.35 Million USD | 100.41% |
| CohBar, Inc. | -5.93 Million USD | 87.523% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 97.512% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 116.207% |
| Legend Biotech Corporation | -949.39 Million USD | 99.922% |
| Mural Oncology plc | -255.84 Million USD | 99.711% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 102.297% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 84.291% |
| Disc Medicine, Inc. | -358.28 Million USD | 99.793% |
| Champions Oncology, Inc. | 4.81 Million USD | 115.378% |
| REGENXBIO Inc. | 54.76 Million USD | 101.351% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -175.188% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 99.51% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 91.789% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 99.083% |
| Vaxart, Inc. | -8.24 Million USD | 91.021% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 98.525% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 99.418% |
| Cellectis S.A. | -43.85 Million USD | 98.313% |
| Longeveron Inc. | -2.9 Million USD | 74.553% |
| Repare Therapeutics Inc. | -107.85 Million USD | 99.314% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 100.076% |
| Inozyme Pharma, Inc. | 12 Million USD | 106.165% |
| Revolution Medicines, Inc. | -608.2 Million USD | 99.878% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 39.837% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 99.721% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 99.507% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 95.271% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.992% |
| Denali Therapeutics Inc. | -74.86 Million USD | 99.012% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 93.829% |
| Veru Inc. | 4.77 Million USD | 115.481% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 93.42% |
| Cingulate Inc. | 3.08 Million USD | 124.005% |
| Passage Bio, Inc. | 4.58 Million USD | 116.14% |
| Context Therapeutics Inc. | -14.44 Million USD | 94.879% |
| Exicure, Inc. | 5.84 Million USD | 112.652% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 99.679% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 98.13% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 104.716% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 98.742% |
| Nuvalent, Inc. | -335.38 Million USD | 99.779% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 142.668% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 99.006% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 91.676% |
| OmniAb, Inc. | 9.2 Million USD | 108.041% |
| Anew Medical, Inc. | 1.43 Million USD | 151.659% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 104.517% |
| Lipocine Inc. | -4.75 Million USD | 84.436% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 99.326% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 104.859% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 98.539% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 102.973% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 88.99% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 98.876% |
| Ocugen, Inc. | -32.52 Million USD | 97.725% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 99.135% |
| Q32 Bio Inc. | -37.94 Million USD | 98.05% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -17.834% |
| Alumis Inc. Common Stock | -13.52 Million USD | 94.53% |
| Equillium, Inc. | -22.39 Million USD | 96.695% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 97.106% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 97.732% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -198.489% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 100.552% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 123.139% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 325.307% |
| Dominari Holdings Inc. | 195 Thousand USD | 479.487% |
| Edesa Biotech, Inc. | -5.26 Million USD | 85.95% |
| vTv Therapeutics Inc. | -8.91 Million USD | 91.701% |
| Bio-Techne Corporation | 267.74 Million USD | 100.276% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 95.435% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 99.373% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 91.194% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 94.151% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 99.698% |
| Nkarta, Inc. | 57.29 Million USD | 101.291% |
| BioCardia, Inc. | 212 Thousand USD | 449.057% |
| Iterum Therapeutics plc | 13.43 Million USD | 105.507% |